Albany Molecular Research Inc. (AMRI) Shares Down 1.5%
Albany Molecular Research Inc. (NASDAQ:AMRI)’s share price was down 1.5% during mid-day trading on Thursday . The stock traded as low as $14.80 and last traded at $14.83, with a volume of 102,588 shares changing hands. The stock had previously closed at $15.05.
Separately, Morgan Stanley reaffirmed a “buy” rating and issued a $17.00 target price on shares of Albany Molecular Research in a report on Friday, August 5th.
The company’s 50-day moving average is $14.49 and its 200-day moving average is $14.67. The stock’s market cap is $508.27 million.
Albany Molecular Research (NASDAQ:AMRI) last released its earnings results on Thursday, August 4th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.32 by $0.04. The business had revenue of $116.50 million for the quarter, compared to analysts’ expectations of $123.10 million. Analysts expect that Albany Molecular Research Inc. will post $1.09 EPS for the current year.
In other news, Director Kevin Oconnor sold 5,000 shares of Albany Molecular Research stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $14.41, for a total transaction of $72,050.00. Following the completion of the transaction, the director now directly owns 52,955 shares in the company, valued at $763,081.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.